Archive for 2009

  • 石川哲也,畑田万紀子,原田 恵嘉,吉村和久, 松下修三: 実験室HIV-1 R5株を用いたin vitro CCR5阻害薬 (maraviroc) 耐性ウイルス誘導の試み第23回日本エイズ学会学術集会・総会.  2009.11.26-28 名古屋

  • 原田 恵嘉,吉村和久, 松下修三: 最近分離した7種の臨床HIV-1株を用いたin vitro ラルテグラビル耐性ウイルス誘導.  第23回日本エイズ学会学術集会・総会.  2009.11.26-28 名古屋

  • 吉村和久: ケモカインレセプター阻害剤の臨床的研究〜臨床分離株を用いたマラビロック耐性誘導〜. 第23回に本エイズ学会学術集会・総会.  2009.11.26-28 名古屋

  • 松下修三:エンベロープの進化と中和抗体. シンポジウムHIV細胞侵入とその防御機構. 第23回日本エイズ学会学術集会・総会.  2009.11.26-28 名古屋

  • 畑田万紀子、吉村和久、原田惠嘉、松下修三:抗HIV-1V3抗体からの逃避過程で挿入される V2領域の糖鎖が保存されるメカニズム-HIV-1の進化における耐性度と増殖能のバランスに関する考察- 第57回日本ウイルス学会学術集会. 2009.10.25-27 東京.

  • Narahara C, Hatada M, Harada S., Yoshimura, K,. Matsushita S,: A primary R5 isolate undergoes different escape pathway during in vitro selection with low or high concentration of an anti-V3 monoclonal antibody. AIDS Vaccine 2009, 2009.10.19-22, Paris.

  • Matsushita S: Accumulation of multiple functional mutations in HIV-1 gp120 is involved in the development of neutralization escape under pressure of neutralizing antibody in vitro. Kumamoto AIDS Seminar GCOE Joint International Symposium- Satellite Symposium, 2009.9.30, Aso, Kumamoto.

  • Yoshimura K, Matsushita S: In vitro induction of HIV-1 resistant to a CCR5. Kumamoto AIDS Seminar GCOE Joint International Symposium- Satellite Symposium, 2009.9.30, Aso, Kumamoto

  • Matsushita S. Narahara C, Nishida Y, Honda A., Harada S., Yoshimura K.: Polyclonal antibody response against gp120 including antibodies to V3, CD4bs and CD4i epitopes account or broad neutralization. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto.

  • Hatada M. Yoshimura K., Harada S, and Matsushita S.:Mechanism of maintaining a glycan-insertion in HIV-1 gp120 V2 region under pressure of a potent neutralizing antibody in vitro. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto.

  • Ishikawa T., Yoshimura K., Hatada M. Harada S, and Matsushita S.: Mutations in gp120 of R5 HIV-1 laboratory isolate induced by the in vitro selection of maraviroc confer highly sensitive to anti-V3 monoclonal antibody. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto

  • Yoshimura K., Harada S, Hatada M. and Matsushita S.: In vitro induction of HIV-1 resistant to a CCR5 antagonist maraviroc. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto

  • Harada S, Yoshimura K., and Matsushita S.: Generation of an integrase inhibitor raltegravir resistant variants using recent primary isolates, X4, R5 and dual/mix HIV-1. 10thKumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto

  • Matsushita S, Narahara C, Morizono M, Nishida Y, Honda-Shibata A, Harada S, Yoshimura K: Polyclonal antibody response against gp120 including antibodies to V3, CD4bs and CD4i eppitopes account or broad neutralizaion. 5th Conference on HIV Pathogenesis, Treatment and prevention. 2009.7.19-22,Cape Town,South Africa

  • 松下修三:HIV-1に対する中和単クローン抗体の治療応用に向けた基礎研究. 第9回日本蛋白質化学学会 2009.5.20-22. 熊本

  • Yoshimura, K, Harada S., Hatada, M., Matsushita S.:Mutations in V4 and C4 regions of the HIV-1 CRF-BC envelope induced by the in vitro selection of Maraviroc Confer cross-resistance to other CCR5 inhibitors. 16th Conference on Trtroviruses and Opportunistic Infections(CROI 2009). 2009 2..8-11, Montreal, Canada